Therapy Name | BIND-014 |
Therapy Description |
BIND-014 is a docetaxel-containing nanoparticle targeted to prostate-specific membrane antigen (PSMA) that gradually releases docetaxel, resulting in tumor cell death (PMID: 26847057). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BIND-014 | BIND-014 is a docetaxel-containing nanoparticle targeted to prostate-specific membrane antigen (PSMA) that gradually releases docetaxel, resulting in tumor cell death (PMID: 26847057). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | Unknown unknown | Advanced Solid Tumor | not applicable | BIND-014 | Phase I | Actionable | In a Phase I clinical trial, BIND-014 treatment resulted in partial response in 10% (5/52) of patients with advanced solid tumors, and complete response in a cervical cancer patient (PMID: 26847057). | 26847057 | Unknown unknown | cervical cancer | not applicable | BIND-014 | Phase I | Actionable | In a Phase I clinical trial, BIND-014 treatment resulted in a complete response in a cervical cancer patient (PMID: 26847057). | 26847057 |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|---|---|---|---|
NCT02479178 | Phase II | BIND-014 | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2) | Terminated |